-
An algorithm for drug-resistant epilepsy in Danish national registers Brain (IF 10.6) Pub Date : 2024-09-10 Eva Bølling-Ladegaard, Julie W Dreier, Jakob Christensen
Patients with drug-resistant epilepsy (DRE) have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life. Identification of persons with DRE in administrative data can allow for effective large-scale research, and we therefore aimed to construct an algorithm for identification of DRE in Danish nation-wide health registers. We used a previously generated
-
Visual hallucinations in Parkinson's disease: spotlight on central cholinergic dysfunction Brain (IF 10.6) Pub Date : 2024-09-07 Anna Ignatavicius, Elie Matar, Simon J G Lewis
Visual hallucinations are a common non-motor feature of Parkinson’s disease and have been associated with accelerated cognitive decline, increased mortality and early institutionalisation. Despite their prevalence and negative impact on patient outcomes, the repertoire of treatments aimed at addressing this troubling symptom is limited. Over the last two decades, significant contributions have been
-
Iatrogenic harm in functional neurological disorder Brain (IF 10.6) Pub Date : 2024-09-07 Caoimhe Mcloughlin, Wei Hao Lee, Alan Carson, Jon Stone
Functional Neurological Disorder (FND) is continuing to gain increasing recognition globally as a valid and potentially treatable disorder. Iatrogenic harm towards patients with FND is significant however, and has been around for centuries. Despite advances in our understanding around the aetiology, pathophysiology, and treatment of FND, many aspects of such harm continue to persist. Avoidance of iatrogenic
-
Longitudinal analysis of glymphatic function in amyotrophic lateral sclerosis and primary lateral sclerosis Brain (IF 10.6) Pub Date : 2024-09-06 Rachel J Sharkey, Filomeno Cortese, Bradley G Goodyear, Lawrence W Korngut, Sarah M Jacob, Keith A Sharkey, Sanjay Kalra, Minh Dang Nguyen, Richard Frayne, Gerald Pfeffer
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of motor neurons in the brain and spinal cord. Accumulation of misfolded proteins is central in the pathogenesis of ALS and the glymphatic system is emerging as a potential therapeutic target to reduce proteinopathy. Using diffusion tensor imaging analysis along the perivascular spaces (DTI-ALPS) to assess glymphatic function, we perform
-
Intracerebral delivery of antiseizure medications by microinvasive neural implants Brain (IF 10.6) Pub Date : 2024-09-06 Hannah D Jackson, Max J Cotler, Gerald W Saunders, Carena A Cornelssen, Peter J West, Cameron S Metcalf, Karen S Wilcox, Michael J Cima
Focal epilepsy is a difficult disease to treat as two-thirds of patients will not respond to oral antiseizure medications (ASMs) or have severe off-target effects that lead to drug discontinuation. Current non-pharmaceutical treatment methods (resection or ablation) are underutilized due to the associated morbidities, invasive nature, and inaccessibility of seizure foci. Less invasive non-ablative
-
-
Deciphering the physiopathology of neurodevelopmental disorders using brain organoids Brain (IF 10.6) Pub Date : 2024-09-02 Olivier Dionne, Salomé Sabatié, Benoit Laurent
Neurodevelopmental disorders (NDD) encompass a range of conditions marked by abnormal brain development in conjunction with impaired cognitive, emotional, and behavioural functions. Transgenic animal models, mainly rodents, traditionally served as key tools for deciphering the molecular mechanisms driving NDD physiopathology, and significantly contributed to the development of pharmacological interventions
-
Motivation in Parkinson’s disease: apathetic before you know it Brain (IF 10.6) Pub Date : 2024-08-29 Sanjay G Manohar
This scientific commentary refers to ‘Putaminal dopamine modulates movement motivation in Parkinson’s disease’ by Banwinkler et al. (https://doi.org/10.1093/brain/awae214).
-
Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model Brain (IF 10.6) Pub Date : 2024-08-29 Wioleta M Zelek, Ryan J Bevan, Jacqui Nimmo, Maarten Dewilde, Bart De Strooper, B Paul Morgan
Complement activation is implicated in driving brain inflammation, self-cell damage and progression of injury in Alzheimer's disease and other neurodegenerative diseases. Here, we investigate the impact of brain delivery of a complement-blocking antibody on neurodegeneration in an Alzheimer's mouse model. We engineered a brain-penetrant recombinant antibody targeting the pro-inflammatory membrane attack
-
Dysregulation of muscle cholesterol transport in amyotrophic lateral sclerosis. Brain (IF 10.6) Pub Date : 2024-08-28 Delphine Sapaly,Flore Cheguillaume,Laure Weill,Zoé Clerc,Olivier Biondi,Sabrina Bendris,Céline Buon,Rasha Slika,Elsie Piller,Venkat Krishnan Sundaram,Andreia da Silva Ramos,Maria Del Mar Amador,Timothée Lenglet,Rabab Debs,Nadine Le Forestier,Pierre-François Pradat,François Salachas,Lucette Lacomblez,Adèle Hesters,Didier Borderie,David Devos,Claude Desnuelle,Anne-Sophie Rolland,Baptiste Periou,Stéphane
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting motor neurons, with a typical lifespan of 3-5 years. Altered metabolism is a key feature of ALS that strongly influences prognosis, with an increase in whole-body energy expenditure and changes in skeletal muscle metabolism, including greater reliance on fat oxidation. Dyslipidemia has been described in ALS as
-
Amyloid-β-activated microglia can induce compound proteinopathies Brain (IF 10.6) Pub Date : 2024-08-28 Sang Hwan Lee, Eun-Jin Bae, Dayana Perez-Acuna, Min Kyo Jung, Jong Won Han, Inhee Mook-Jung, Seung-Jae Lee
Neuropathological features of Alzheimer’s disease include amyloid plaques, neurofibrillary tangles and Lewy bodies, with the former preceding the latter two. However, it is not fully understood how these compound proteinopathies are interconnected. Here, we show that transplantation of amyloid-β oligomer-activated microglia into the striatum of naïve mice was sufficient to generate all the features
-
Neurophysiological markers of motor compensatory mechanisms in early Parkinson's disease. Brain (IF 10.6) Pub Date : 2024-08-27 Massimiliano Passaretti,Roberto Cilia,Sara Rinaldo,Davide Rossi Sebastiano,Eva Orunesu,Grazia Devigili,Arianna Braccia,Giulia Paparella,Martina De Riggi,Thilo van Eimeren,Antonio Paolo Strafella,Paola Lanteri,Alfredo Berardelli,Matteo Bologna,Roberto Eleopra
Compensatory mechanisms in Parkinson's disease are defined as the changes that the brain uses to adapt to neurodegeneration and progressive dopamine reduction. Motor compensation in early Parkinson's disease could, in part, be responsible for a unilateral onset of clinical motor signs despite the presence of bilateral nigrostriatal degeneration. Although several mechanisms have been proposed for compensatory
-
The systemic complexity of a monogenic disease: the molecular network of spinal muscular atrophy Brain (IF 10.6) Pub Date : 2024-08-26 Ines Tapken, Theresa Schweitzer, Martina Paganin, Tobias Schüning, Nora T Detering, Gaurav Sharma, Moritz Niesert, Afshin Saffari, Daniela Kuhn, Amy Glynn, Federica Cieri, Pamela Santonicola, Claire Cannet, Florian Gerstner, Kiterie M E Faller, Yu-Ting Huang, Rashmi Kothary, Thomas H Gillingwater, Elia Di Schiavi, Christian M Simon, Niko Hensel, Andreas Ziegler, Gabriella Viero, Andreas Pich, Peter
Monogenic diseases are well-suited paradigms for the causal analysis of disease-driving molecular patterns. Spinal Muscular Atrophy (SMA) is one such monogenic model caused by mutation or deletion of the Survival of motor neuron 1 (SMN1) gene. Although several functions of the SMN protein have been studied, single functions and pathways alone do not allow to identify critical disease-driving molecules
-
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study Brain (IF 10.6) Pub Date : 2024-08-22 Andrea Calcagno, Jessica Cusato, Paola Cinque, Giulia Marchetti, Davide Bernasconi, Mattia Trunfio, Elena Bruzzesi, Stefano Rusconi, Arianna Gabrieli, Antonio Muscatello, Andrea Antinori, Diego Ripamonti, Roberto Gulminetti, Miriam Antonucci, Silvia Nozza
It is debated whether central nervous system involvement begins during acute HIV infection in persons without meningitis/encephalitis and if specific antiretroviral drugs or combinations would be beneficial. Neurologically asymptomatic participants enrolled in a randomized and controlled study comparing three combination antiretroviral regimens (tenofovir alafenamide/emtricitabine plus dolutegravir
-
GGC repeat expansions in NOTCH2NLC cause uN2CpolyG cerebral amyloid angiopathy Brain (IF 10.6) Pub Date : 2024-08-22 Lei Bao, Xiaowen Li, Jin Tian, Lulu Wang, Ying Ji, Yingying Cui, Wen Sun, Jing Zhang, Man Xia, Pinyi Zhu, Guiyun Cui, Hao Chen
The expansion of GGC repeats within NOTCH2NLC leads to the translation of the uN2CpolyG protein, the primary pathogenic factor in neuronal intranuclear inclusion disease (NIID). This study aims to explore the deposition of uN2CpolyG as an amyloid in the vessel wall, leading to uN2CpolyG cerebral amyloid angiopathy (CAA)-related cerebral microbleeds (CMBs). A total of 97 patients with genetically confirmed
-
Targeting spinal mechanistic target of rapamycin complex 2 alleviates inflammatory and neuropathic pain Brain (IF 10.6) Pub Date : 2024-08-20 Calvin Wong, Luis David Rodriguez-Hernandez, Kevin C Lister, Ning Gu, Weihua Cai, Mehdi Hooshmandi, Jonathan Fan, Nicole Brown, Vivienne Nguyen, Alfredo Ribeiro-da-Silva, Robert P Bonin, Arkady Khoutorsky
The development and maintenance of chronic pain involves the reorganization of spinal nociceptive circuits. The mechanistic target of rapamycin complex 2 (mTORC2), a central signaling hub that modulates both actin-dependent structural changes and mTORC1-dependent mRNA translation, plays key roles in hippocampal synaptic plasticity and memory formation. However, its function in spinal plasticity and
-
Direct current stimulation modulates prefrontal cell activity and behaviour without inducing seizure-like firing Brain (IF 10.6) Pub Date : 2024-08-19 Daniel J Fehring, Seiichirou Yokoo, Hiroshi Abe, Mark J Buckley, Kentaro Miyamoto, Shapour Jaberzadeh, Tetsuo Yamamori, Keiji Tanaka, Marcello G P Rosa, Farshad A Mansouri
Transcranial direct current stimulation (tDCS) has garnered significant interest for its potential to enhance cognitive functions and as a therapeutic intervention in various cognitive disorders. However, the clinical application of tDCS has been hampered by significant variability in its cognitive outcomes. Furthermore, the widespread use of tDCS has raised concerns regarding its safety and efficacy
-
Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration Brain (IF 10.6) Pub Date : 2024-08-19 Maura Malpetti, Peter Swann, Kamen A Tsvetanov, Leonidas Chouliaras, Alexandra Strauss, Tanatswa Chikaura, Alexander G Murley, Nicholas J Ashton, Peter Barker, P Simon Jones, Tim D Fryer, Young T Hong, Thomas E Cope, George Savulich, Duncan Street, W Richard Bevan-Jones, Timothy Rittman, Kaj Blennow, Henrik Zetterberg, Franklin I Aigbirhio, John T O’Brien, James B Rowe
Neuroinflammation is an important pathogenic mechanism in many neurodegenerative diseases, including those caused by frontotemporal lobar degeneration (FTLD). Postmortem and in vivo imaging studies have shown brain inflammation early in these conditions, proportionate to symptom severity and rate of progression. However, evidence for corresponding blood markers of inflammation and their relationship
-
Evolutionary perspectives on mRNA signatures of neurodegeneration-related brain remodelling Brain (IF 10.6) Pub Date : 2024-08-19 Ting Shen, Corey T McMillan
This scientific commentary refers to ‘Frontotemporal lobar degeneration targets brain regions linked to expression of recently evolved genes’ by Pasquini et al. (https://doi.org/10.1093/brain/awae205).
-
Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington disease models Brain (IF 10.6) Pub Date : 2024-08-15 Marina Sogorb-Gonzalez, Christian Landles, Nicholas S Caron, Anouk Stam, Georgina Osborne, Michael R Hayden, David Howland, Sander van Deventer, Gillian P Bates, Astrid Vallès, Melvin Evers
Huntington disease (HD) is a fatal neurodegenerative disease caused by a trinucleotide repeat expansion in exon 1 of the huntingtin gene (HTT) resulting in toxic gain-of-function and cell death. Despite its monogenic cause, the pathogenesis of HD is highly complex and increasing evidence indicates that, in addition to the full-length (FL) mutant HTT protein, the expanded exon 1 HTT (HTTexon1) protein
-
JC virus spread is potentiated by glial replication and demyelination-linked glial proliferation Brain (IF 10.6) Pub Date : 2024-08-12 Cui Li, Nguyen P T Huynh, Steven J Schanz, Martha S Windrem, Steven A Goldman
Progressive multifocal leukoencephalopathy (PML) is a demyelinating infection of the immunosuppressed brain, mediated by the gliotropic polyomavirus JCV. JCV replicates in human glial progenitor cells and astrocytes, which undergo viral T antigen-triggered mitosis, enabling viral replication. We asked if JCV spread might therefore be accelerated by glial proliferation. Using both in vitro analysis
-
Cytoarchitectonic gradients of laminar degeneration in behavioural variant frontotemporal dementia Brain (IF 10.6) Pub Date : 2024-08-08 Daniel T Ohm, Sharon X Xie, Noah Capp, Sanaz Arezoumandan, Katheryn A Q Cousins, Katya Rascovsky, David A Wolk, Vivianna M Van Deerlin, Edward B Lee, Corey T McMillan, David J Irwin
Behavioral variant frontotemporal dementia (bvFTD) is a clinical syndrome primarily caused by either tau (bvFTD-tau) or TDP-43 (bvFTD-TDP) proteinopathies. We previously found lower cortical layers and dorsolateral regions accumulate greater tau than TDP-43 pathology; however, patterns of laminar neurodegeneration across diverse cytoarchitecture in bvFTD is understudied. We hypothesized that bvFTD-tau
-
Dysfunction of the magnocellular subdivision of the visual thalamus in developmental dyslexia Brain (IF 10.6) Pub Date : 2024-08-08 Christa Müller-Axt, Louise Kauffmann, Cornelius Eichner, Katharina von Kriegstein
Developmental dyslexia (DD) is one of the most common learning disorders, affecting millions of children and adults worldwide. To date, scientific research has attempted to explain DD primarily based on pathophysiological alterations in the cerebral cortex. In contrast, several decades ago, pioneering research on five post-mortem human brains suggested that a core characteristic of DD might be morphological
-
An alternative therapeutic approach to haematopoetic stem cell transplantation in early cerebral adrenoleukodystrophy. Brain (IF 10.6) Pub Date : 2024-08-07 Jeremy Chataway,Charles Wade,Elaine Murphy,David S Lynch
-
Chloride deregulation and GABA depolarization in MTOR related malformations of cortical development Brain (IF 10.6) Pub Date : 2024-08-07 Naziha Bakouh, Reyes Castaño-Martín, Alice Metais, Emanuela Loredana Dan, Estelle Balducci, Cerina Chhuon, Joanna Lepicka, Giulia Barcia, Emma Losito, Stéphane Lourdel, Gabrielle Planelles, Raul C Muresan, Vasile Vlad Moca, Anna Kaminska, Marie Bourgeois, Nicole Chemaly, Yasmine Rguez, Stéphane Auvin, Gilles Huberfeld, Pascale Varlet, Vahid Asnafi, Ida Chiara Guerrera, Edor Kabashi, Rima Nabbout, Sorana
Focal Cortical Dysplasia, Hemimegalencephaly and Cortical Tuber are pediatric epileptogenic malformations of cortical development (MCDs) frequently pharmaco-resistant and mostly surgically treated by the resection of epileptic cortex. Availability of cortical resection samples allowed significant mechanistic discoveries directly from human material. Causal brain somatic or germline mutations in the
-
Exploring the impact of somatic variant burden on seizures in focal cortical dysplasia. Brain (IF 10.6) Pub Date : 2024-09-03 Meethila Gade,Erin L Heinzen
-
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis Brain (IF 10.6) Pub Date : 2024-08-05 Enric Monreal, José Ignacio Fernández-Velasco, Roberto Álvarez-Lafuente, Susana Sainz de la Maza, María Isabel García-Sánchez, Sara Llufriu, Bonaventura Casanova, Manuel Comabella, Sergio Martínez-Yélamos, Daniela Galimberti, Lluís Ramió-Torrentà, María Luisa Martínez-Ginés, Yolanda Aladro, Lucía Ayuso, José Enrique Martínez-Rodríguez, Luis Brieva, Noelia Villarrubia, Sara Eichau, Javier Zamora, Alexander
The potential of combining serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels to predict disability worsening in multiple sclerosis (MS) remains underexplored. We aimed to investigate whether sNfL and sGFAP values identify distinct subgroups of patients according to the risk of disability worsening and their response to disease-modifying treatments (DMTs). This
-
Exploring the link between dystrophic microglia and the spread of Alzheimer's neuropathology Brain (IF 10.6) Pub Date : 2024-08-05 Ryan K Shahidehpour, Peter T Nelson, Yuriko Katsumata, Adam D Bachstetter
Genetics and other data modalities indicate that microglia play a critical role in Alzheimer’s disease (AD) progression, but details of microglia’s disease-driving influence are poorly understood. Microglial cells can be parsed into subtypes based on their histologic appearance. One microglia subtype, termed dystrophic microglia, is characterised structurally by fragmented processes and cytoplasmic
-
Unravelling the origin of the reward positivity: a human intracranial event-related brain potential study Brain (IF 10.6) Pub Date : 2024-08-05 Joyce Oerlemans, Ricardo J Alejandro, Dirk Van Roost, Paul Boon, Veerle De Herdt, Alfred Meurs, Clay B Holroyd
The reward positivity (RewP) is an event-related brain potential (ERP) component that emerges approximately 250 to 350 milliseconds (ms) after receiving reward-related feedback stimuli and is believed to be important for reinforcement learning and reward processing. Although numerous localization studies have indicated that the anterior cingulate cortex (ACC) is the neural generator of this component
-
-
The human hippocampus contributes to short-term memory. Brain (IF 10.6) Pub Date : 2024-08-01 Masud Husain
-
Correction to: Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis. Brain (IF 10.6) Pub Date : 2024-08-01
-
The challenge of assessing invasive biomarkers for epilepsy surgery. Brain (IF 10.6) Pub Date : 2024-08-01 Nicolas Roehri,Serge Vulliemoz,Stanislas Lagarde
-
Reply: The challenge of assessing invasive biomarkers for epilepsy surgery and To plan efficacious epilepsy surgery. Brain (IF 10.6) Pub Date : 2024-08-01 Wen Shi,Uri Eden,Mark A Kramer,Catherine J Chu
-
The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics. Brain (IF 10.6) Pub Date : 2024-08-01 Juan Carlos Rubilar,Tiago Fleming Outeiro,Andrés D Klein
Parkinson's disease is a neurodegenerative disorder primarily known for typical motor features that arise due to the loss of dopaminergic neurons in the substantia nigra. However, the precise molecular aetiology of the disease is still unclear. Several cellular pathways have been linked to Parkinson's disease, including the autophagy-lysosome pathway, α-synuclein aggregation and mitochondrial function
-
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study Brain (IF 10.6) Pub Date : 2024-08-01 Ana Westenberger, Volha Skrahina, Tatiana Usnich, Christian Beetz, Eva-Juliane Vollstedt, Björn-Hergen Laabs, Jefri J Paul, Filipa Curado, Snezana Skobalj, Hanaa Gaber, Maria Olmedillas, Xenia Bogdanovic, Najim Ameziane, Nathalie Schell, Jan Olav Aasly, Mitra Afshari, Pinky Agarwal, Jason Aldred, Fernando Alonso-Frech, Roderick Anderson, Rui Araújo, David Arkadir, Micol Avenali, Mehmet Balal, Sandra
Estimates of the spectrum and frequency of pathogenic variants in Parkinson’s disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the clinical trial stage, a major obstacle in conducting these trials is that PD patients are largely unaware of their genetic status and, therefore, cannot be recruited
-
Increase of HCN current in SOD1-associated amyotrophic lateral sclerosis Brain (IF 10.6) Pub Date : 2024-08-01 Hsing-Jung Lai, Yih-Chih Kuo, Chen-Hung Ting, Chih-Chao Yang, Chia-Hsin Kao, Yi-Chieh Tsai, Chi-Chao Chao, Hsueh-Wen Hsueh, Pei-Feng Hsieh, Hsiang-Yu Chang, I-Fan Wang, Li-Kai Tsai
The clinical manifestations of sporadic amyotrophic lateral sclerosis (ALS) vary widely. However, the current classification of ALS is mainly based on clinical presentations, while the roles of electrophysiological and biomedical biomarkers remain limited. Herein, we investigated a group of patients with sporadic ALS and an ALS mouse model with superoxide dismutase 1 (SOD1)/G93A transgenes using nerve
-
Clinical genetic testing in Parkinson’s disease should become part of routine patient care Brain (IF 10.6) Pub Date : 2024-08-01 Ziv Gan-Or
This scientific commentary refers to ‘Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s Disease Study’ by Westenberger et al. (https://doi.org/10.1093/brain/awae188) and ‘Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study’ by Cook et al. (https://doi.org/10.1093/brain/awae142).
-
Identifying novel risk genes in intracranial aneurysm by integrating human proteomes and genetics Brain (IF 10.6) Pub Date : 2024-08-01 Congyan Wu, Hanchen Liu, Qiao Zuo, Aimin Jiang, Chuanchuan Wang, Nan Lv, Ruyue Lin, Yonghui Wang, Kang Zong, Yanpeng Wei, Qinghai Huang, Qiang Li, Pengfei Yang, Rui Zhao, Jianmin Liu
Genome-wide association studies (GWAS) have become increasingly popular for detecting numerous loci associated with intracranial aneurysm (IA), but how these loci function remains unclear. In this study, we employed an integrative analytical pipeline to efficiently transform genetic associations and identify novel genes for IA. Using multidimensional high-throughput data, we integrated proteome-wide
-
Biallelic null variants in PNPLA8 cause microcephaly by reducing the number of basal radial glia Brain (IF 10.6) Pub Date : 2024-08-01 Yuji Nakamura, Issei S Shimada, Reza Maroofian, Micol Falabella, Maha S Zaki, Masanori Fujimoto, Emi Sato, Hiroshi Takase, Shiho Aoki, Akihiko Miyauchi, Eriko Koshimizu, Satoko Miyatake, Yuko Arioka, Mizuki Honda, Takayoshi Higashi, Fuyuki Miya, Yukimune Okubo, Isamu Ogawa, Annarita Scardamaglia, Mohammad Miryounesi, Sahar Alijanpour, Farzad Ahmadabadi, Peter Herkenrath, Hormos Salimi Dafsari, Clara
Patatin-like phospholipase domain-containing lipase 8 (PNPLA8), one of the calcium-independent phospholipase A2 enzymes, is involved in various physiological processes through the maintenance of membrane phospholipids. Biallelic variants in PNPLA8 have been associated with a range of paediatric neurodegenerative disorders. However, the phenotypic spectrum, genotype–phenotype correlations and the underlying
-
Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study Brain (IF 10.6) Pub Date : 2024-07-30 Lola Cook, Jennifer Verbrugge, Tae-Hwi Schwantes-An, Jeanine Schulze, Tatiana Foroud, Anne Hall, Karen S Marder, Ignacio F Mata, Niccolò E Mencacci, Martha A Nance, Michael A Schwarzschild, Tanya Simuni, Susan Bressman, Anne-Marie Wills, Hubert H Fernandez, Irene Litvan, Kelly E Lyons, Holly A Shill, Carlos Singer, Thomas F Tropea, Nora Vanegas Arroyave, Janfreisy Carbonell, Rossy Cruz Vicioso, Linn
Variants in seven genes (LRRK2, GBA1, PRKN, SNCA, PINK1, PARK7 and VPS35) have been formally adjudicated as causal contributors to Parkinson’s disease; however, individuals with Parkinson’s disease are often unaware of their genetic status since clinical testing is infrequently offered. As a result, genetic information is not incorporated into clinical care, and variant-targeted precision medicine
-
Autoimmune ‘secondary synaptopathies’: do NMDAR antibodies cause a primary extra-synaptopathy? Brain (IF 10.6) Pub Date : 2024-07-29 Meng Zhao, David R Lynch, Sarosh R Irani
This scientific commentary refers to ‘NMDA receptor autoantibodies primarily impair the extrasynaptic compartment’ by Jamet et al. (https://doi.org/10.1093/brain/awae163).
-
Proteostasis as a fundamental principle of Tau immunotherapy Brain (IF 10.6) Pub Date : 2024-07-29 Esteban Cruz, Rebecca M Nisbet, Pranesh Padmanabhan, Ashley J van Waardenberg, Mark E Graham, Godfrey Nkajja, Swara Tapaswi, Bradley J Connor, Phil Robinson, Jürgen Götz
The microtubule-associated protein Tau is a driver of neuronal dysfunction in Alzheimer’s disease and other tauopathies. In this process, Tau initially undergoes subtle changes to its abundance, subcellular localisation and a vast array of post-translational modifications including phosphorylation, that progressively result in the protein’s somatodendritic accumulation and dysregulation of multiple
-
Sink into the epileptogenic zone: findings from directed SEEG functional connectivity decomposition Brain (IF 10.6) Pub Date : 2024-07-27 Stanislas Lagarde, Fabrice Bartolomei
This scientific commentary refers to ‘The interictal suppression hypothesis is the dominant differentiator of seizure onset zones in focal epilepsy’ by Doss et al. (https://doi.org/10.1093/brain/awae189).
-
Prenatal assessment of brain malformations on neuroimaging: an expert panel review Brain (IF 10.6) Pub Date : 2024-07-26 Ivana Pogledic, Kshitij Mankad, Mariasavina Severino, Tally Lerman-Sagie, Andras Jakab, Efrat Hadi, Anna C Jansen, Nadia Bahi-Buisson, Natalya Di Donato, Renske Oegema, Christian Mitter, Ivan Capo, Matthew T Whitehead, Parthiv Haldipur, Grazia Mancini, Thierry A G M Huisman, Andrea Righini, Bill Dobyns, James A Barkovich, Natasa Jovanov Milosevic, Gregor Kasprian, Maarten Lequin
Brain malformations represent a heterogeneous group of abnormalities of neural morphogenesis, often associated with aberrations of neuronal connectivity and brain volume. Prenatal detection of brain malformations requires a clear understanding of embryology and developmental morphology through the various stages of gestation. This expert panel review is written with the central aim of providing an
-
CSF1R inhibition depletes brain macrophages and reduces brain virus burden in SIV-infected macaques. Brain (IF 10.6) Pub Date : 2024-09-03 Diana G Bohannon,Laurent D Zablocki-Thomas,Evan S Leung,Jinbum K Dupont,Julian B Hattler,Jolanta Kowalewska,Miaoyun Zhao,Jiangtao Luo,Marco Salemi,Angela M Amedee,Qingsheng Li,Marcelo J Kuroda,Woong-Ki Kim
Perivascular macrophages (PVMs) and, to a lesser degree, microglia are targets and reservoirs of HIV and simian immunodeficiency virus (SIV) in the brain. Previously, we demonstrated that colony-stimulating factor 1 receptor (CSF1R) in PVMs was upregulated and activated in chronically SIV-infected rhesus macaques with encephalitis, correlating with SIV infection of PVMs. Herein, we investigated the
-
Differential reorganization of episodic and semantic memory systems in epilepsy-related mesiotemporal pathology Brain (IF 10.6) Pub Date : 2024-07-25 Donna Gift Cabalo, Jordan DeKraker, Jessica Royer, Ke Xie, Shahin Tavakol, Raúl Rodríguez-Cruces, Andrea Bernasconi, Neda Bernasconi, Alexander Weil, Raluca Pana, Birgit Frauscher, Lorenzo Caciagli, Elizabeth Jefferies, Jonathan Smallwood, Boris C Bernhardt
Declarative memory encompasses episodic and semantic divisions. Episodic memory captures singular events with specific spatiotemporal relationships, while semantic memory houses context-independent knowledge. Behavioural and functional neuroimaging studies have revealed common and distinct neural substrates of both memory systems, implicating mesiotemporal lobe (MTL) regions such as the hippocampus
-
State-dependent effects of responsive neurostimulation depend on seizure localization Brain (IF 10.6) Pub Date : 2024-07-25 Sharon Chiang, Ankit N Khambhati, Thomas K Tcheng, Audra Plenys Loftman, Nicholas R Hasulak, Emily A Mirro, Martha J Morrell, Vikram R Rao
Brain-responsive neurostimulation is firmly ensconced among treatment options for drug-resistant focal epilepsy, but over a quarter of patients treated with the RNS System do not experience meaningful seizure reduction. Initial titration of RNS therapy is typically similar for all patients, raising the possibility that treatment response might be enhanced by consideration of patient-specific variables
-
BOK-engaged mitophagy alleviates neuropathology in Alzheimer’s disease Brain (IF 10.6) Pub Date : 2024-07-25 Yang Yang, Hui Chen, Shuwen Huang, Hao Chen, Alexei Verkhratsky, Jianqin Niu, Yibo Qu, Chenju Yi
Mitochondrial malfunction associated with impaired mitochondrial quality control and self-renewal machinery, known as mitophagy, is an under-appreciated mechanism precipitating synaptic loss and cognitive impairments in Alzheimer’s disease (AD). Promoting mitophagy has been shown to improve cognitive function in AD animals. However, the regulatory mechanism was unclear, which formed the aim of this
-
Tomivosertib reduces ectopic activity in dorsal root ganglion neurons from patients with radiculopathy Brain (IF 10.6) Pub Date : 2024-07-25 Yan Li, Megan L Uhelski, Robert Y North, Juliet M Mwirigi, Claudio E Tatsui, Kathleen E McDonough, Juan P Cata, German Corrales, Greg Dussor, Theodore J Price, Patrick M Dougherty
Spontaneous activity in dorsal root ganglion (DRG) neurons is a key driver of neuropathic pain in patients suffering from this largely untreated disease. While many intracellular signalling mechanisms have been examined in preclinical models that drive spontaneous activity, none have been tested directly on spontaneously active human nociceptors. Using cultured DRG neurons recovered during thoracic
-
The ageing central nervous system in multiple sclerosis: the imaging perspective. Brain (IF 10.6) Pub Date : 2024-07-24 Massimo Filippi,Paolo Preziosa,Frederik Barkhof,Olga Ciccarelli,Andrea Cossarizza,Nicola De Stefano,Claudio Gasperini,Ruth Geraldes,Cristina Granziera,Lukas Haider,Hans Lassmann,Monica Margoni,Giuseppe Pontillo,Stefan Ropele,Àlex Rovira,Jaume Sastre-Garriga,Tarek A Yousry,Maria A Rocca,
The interaction between ageing and multiple sclerosis is complex and carries significant implications for patient care. Managing multiple sclerosis effectively requires an understanding of how ageing and multiple sclerosis impact brain structure and function. Ageing inherently induces brain changes, including reduced plasticity, diminished grey matter volume, and ischaemic lesion accumulation. When
-
Decoding the muscle transcriptome of patients with late onset Pompe disease reveals markers of disease progression Brain (IF 10.6) Pub Date : 2024-07-22 Alexandra Monceau, Rasya Gokul Nath, Xavier Suárez-Calvet, Olimpia Musumeci, Antonio Toscano, Biruta Kierdaszuk, Anna Kostera-Pruszczyk, Cristina Domínguez- González, Aurelio Hernández-Lain, Carmen Paradas, Eloy Rivas, George Papadimas, Constantinos Papadopoulos, Margarita Chrysanthou-Piterou, Eduard Gallardo, Montse Olivé, James Lilleker, Mark E Roberts, Domenica Marchese, Giulia Lunazzi, Holger Heyn
Late-onset Pompe Disease (LOPD) is a rare genetic disorder caused by the deficiency of acid alpha-glucosidase leading to progressive cellular dysfunction due to the accumulation of glycogen in the lysosome. The mechanism of relentless muscle damage – a classic manifestation of the disease – has been extensively studied by analysing the whole muscle tissue; however, little, if any, is known about transcriptional
-
Grey matter ageing-related tau astrogliopathy: associations with brain pathologies and cognitive decline Brain (IF 10.6) Pub Date : 2024-07-22 Sonal Agrawal, Lei Yu, Sue E Leurgans, Alifiya Kapasi, Lisa L Barnes, David A Bennett, Patricia A Boyle, Julie A Schneider
Grey matter ARTAG pathology is common in aged brains and detected in multiple brain regions. However, the associations of grey matter ARTAG with Alzheimer’s disease (AD) and other common age-related proteinopathies, as well as clinical phenotypes including Alzheimer’s dementia and cognitive decline remain unclear. We examined 442 decedents (mean age-at-death=90 years, males=32%) from three longitudinal
-
Multiple sclerosis in Denmark (1950–2023): mean age, sex distribution, incidence and prevalence Brain (IF 10.6) Pub Date : 2024-07-20 Rolf P Holm, Malthe F Wandall-Holm, Melinda Magyari
With rising life expectancy and advancements in disease management, we expect the multiple sclerosis population is getting older. However, evidence supporting this hypothesis remains sparse. Our study aimed to determine whether the mean age of the Danish multiple sclerosis population has increased and to analyse the developments in sex distribution, incidence, and prevalence, all of which affect age
-
Presynaptic hyperexcitability reversed by positive allosteric modulation of a GABABR epilepsy variant Brain (IF 10.6) Pub Date : 2024-07-19 Marielle Minere, Martin Mortensen, Valentina Dorovykh, Gary Warnes, Dean Nizetic, Trevor G Smart, Saad B Hannan
GABABRs are key membrane proteins that continually adapt the excitability of the nervous system. These G-protein coupled receptors are activated by the brain’s premier inhibitory neurotransmitter GABA. They are obligate heterodimers composed of GABA-binding GABABR1 and G-protein-coupling GABABR2 subunits. Recently, three variants (G693W, S695I, I705N) have been identified in the gene (GABBR2) encoding
-
Shared patterns of glial transcriptional dysregulation link Huntington’s disease and schizophrenia Brain (IF 10.6) Pub Date : 2024-07-19 Nguyen P T Huynh, Mikhail Osipovitch, Rossana Foti, Janna Bates, Benjamin Mansky, Jose C Cano, Abdellatif Benraiss, Chuntao Zhao, Q Richard Lu, Steven A Goldman
Huntington’s disease and juvenile-onset schizophrenia have long been regarded as distinct disorders. However, both manifest cell-intrinsic abnormalities in glial differentiation, with resultant astrocytic dysfunction and hypomyelination. To assess whether a common mechanism might underlie the similar glial pathology of these otherwise disparate conditions, we used comparative correlation network approaches
-
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation Brain (IF 10.6) Pub Date : 2024-07-18 Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer
Epstein-Barr virus (EBV) infection has long been associated with the development of multiple sclerosis (MS). MS patients have elevated titers of EBV-specific antibodies in serum and show signs of CNS damage only after EBV infection. Regarding CD8+ T-cells, an elevated but ineffective response to EBV was suggested in MS patients, who present with a broader MHC-I-restricted EBV-specific T-cell receptor
-
Combined clinical, structural, and cellular studies discriminate pathogenic and benign TRPV4 variants Brain (IF 10.6) Pub Date : 2024-07-18 Sarah H Berth, Linh Vo, Do Hoon Kwon, Tiffany Grider, Yasmine S Damayanti, Gage Kosmanopoulos, Andrew Fox, Alexander R Lau, Patrice Carr, Jack K Donohue, Maya Hoke, Simone Thomas, Chafic Karim, Alex J Fay, Ethan Meltzer, Thomas O Crawford, Rachelle Gaudet, Michael E Shy, Ute A Hellmich, Seok-Yong Lee, Charlotte J Sumner, Brett A McCray
Dominant mutations in the calcium-permeable ion channel TRPV4 (transient receptor potential vanilloid 4) cause diverse and largely distinct channelopathies, including inherited forms of neuromuscular disease, skeletal dysplasias, and arthropathy. Pathogenic TRPV4 mutations cause gain of ion channel function and toxicity that can be rescued by small molecule TRPV4 antagonists in cellular and animal
-
Disentangling genetic risks for development and progression of Alzheimer’s disease Brain (IF 10.6) Pub Date : 2024-07-17 Niklas Mattsson-Carlgren
This scientific commentary refers to ‘Towards cascading genetic risk in Alzheimer’s disease’ by Altmann et al. (https://doi.org/10.1093/brain/awae176).
-
Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size. Brain (IF 10.6) Pub Date : 2024-07-16 Cato E A Corsten,Beatrijs H A Wokke,Joost Smolders